Starling Oncology reports Q2 revenue up 35%, achieves first positive Adjusted EBITDA

Filed August 6, 2026 · Period ending August 6, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 revenue rose 34.6% to $161.3M; gross profit up 55.2% to $27.2M; Adjusted EBITDA turned positive at $229K vs. $(4.1)M loss in Q2 2025, marking the company's first profitable quarter on that metric.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
• high

  Raised full-year 2026 revenue guidance to $650–$670M from $630–$650M; gross profit to $105–$110M from $97–$107M; narrowed Adjusted EBITDA to $2–$7M from $0–$9M, citing strong first-half results and new contract momentum.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
• high

  Secured exclusivity with a major California partner across all delegated medical groups, adding ~230K capitated lives; signed first delegated contracts outside Florida (Nevada, Oregon); projects ~$150M capitated revenue in 2026.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →